TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: A previous case report demonstrated an 18-year-old male Xp11.2 tRCC patient with ASPL-TFE3 fusion had a favorable response to sorafenib (40).